Polarean Imaging (LSE:POLX) ROCE %: -92.26% (As of Jun. 2025)


What is Polarean Imaging ROCE %?

Polarean Imaging LSE:POLX -20.00% ROCE % is -92.26% as of Jun. 2025. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Polarean Imaging's annualized ROCE % for the quarter that ended in Jun. 2025 was -92.26%.

Polarean Imaging  (LSE:POLX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Polarean Imaging ROCE % Related Terms

Polarean Imaging ROCE % Historical Data

* Premium members only.

The historical data trend for Polarean Imaging's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Polarean Imaging ROCE % Chart

Polarean Imaging Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROCE %
Get a 7-Day Free Trial Premium Member Only -90.36 -66.93 -55.36 -79.65 -79.80

Polarean Imaging Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -85.56 -82.42 -64.70 -63.06 -92.26

Polarean Imaging ROCE % Calculation

Polarean Imaging's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-6.742/( ( (8.598 - 1.74) + (12.491 - 2.451) )/ 2 )
=-6.742/( (6.858+10.04)/ 2 )
=-6.742/8.449
=-79.80 %

Polarean Imaging's ROCE % of for the quarter that ended in Jun. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2025 )  (Q: Dec. 2024 )(Q: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2025 )  (Q: Dec. 2024 )(Q: Jun. 2025 )
=-7.452/( ( (12.491 - 2.451) + (8.161 - 2.047) )/ 2 )
=-7.452/( ( 10.04 + 6.114 )/ 2 )
=-7.452/8.077
=-92.26 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -92.26% mean?
Polarean Imaging (LSE:POLX) has a ROCE % of -92.26% as of Jun. 2025.
Is Polarean Imaging's ROCE % too high?
Polarean Imaging's current ROCE % is -92.26%.
How does Polarean Imaging's ROCE % compare to FOFA and BTCY?
Polarean Imaging's ROCE % of -92.26% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polarean Imaging's current ROCE % is -92.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polarean Imaging stock overvalued right now?
Polarean Imaging (LSE:POLX) has a current ROCE % of -92.26%. The current ROCE % is -92.26%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Polarean Imaging (LSE:POLX), the current ROCE % is -92.26% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Polarean Imaging Business Description

Address 27-28 Eastcastle Street, London, GBR, W1W 8DH
Polarean Imaging PLC designs and manufactures medical drug-device combination companies operating in the high-resolution medical imaging market. Its only operating segment is the development and commercialization of gas polariser devices and ancillary instruments. Geographically, it derives the majority of its revenue from the United States of America and also has a presence in Canada and the United Kingdom. The company generates revenue from products and services such as Polarisers, Parts and Upgrades, Service, and other revenue. Its product portfolio includes 9820 129Xe Hyperpolarizer, 9800 129Xe Hyperpolarizer, Polarean 3777 129Xe Hyperpolarizer Upgrade Module, Polarean 2881 Polarization Measurement Station, and others.